Scandinavian ChemoTech announces the receival of ethics committee approval for a clinical trial with the TSE™ technology at ‘All India Institute of Medical Sciences’ (AIIMS) in India
ChemoTech’s newly started Centre of Excellence (CoE) at the India Sweden Healthcare Innovation Centre at AIIMS in Jodhpur, in India has progressed into an initial approval for its Ethical committee for Head & Neck cancer.
AIIMS, Jodhpur in India has received the Ethical Approval for “A clinical applicability study of the tumour specific electroporation technique for patients with locally advanced or recurrent head & neck cancer using IQwave 3.0 CE”.
The Investigator-Initiated Trial (IIT) was presented to the Ethical board by the Principal Investigator Dr. Jeewan Ram Vishnoi, Associate Professor, Department of Surgical Oncology, AIIMS, Jodhpur
The trial s conducted as part of the India-Sweden Healthcare Innovation Centre, a collaboration between AIIMS Delhi, AIIMS Jodhpur and Business Sweden - Swedish Trade Commissioner’s Office.
The trial will start the enrolment of patients as soon as some changes to the protocol has been submitted.
"Tumour Specific Electroporation (TSE) is an evolving paradigm in the treatment of solid tumours with growing evidence not only for regional tumour control in a palliative care setting but also in earlier lines of curative treatment approaches. " - says Dr. Suhail Mufti Medical Adviser for ChemoTech
“We are very pleased that we are about to start one of the largest clinical projects in the history of ChemoTech. Even if we to date have treated hundreds of patients with different indications, we are still at the beginning of our journey. It is after reaching success in clinical trials with skilled and well-acknowledged organizations like AIIMS that our technology will come closer to becoming a contribution to standard therapy.” - says Mohan Frick CEO
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-07-2022 08:55 CET.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
